The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines
Publication in refereed journal


引用次數
替代計量分析
.

其它資訊
摘要The activity of the histone deacetylase inhibitor PXD101 was investigated in three hepatocellular carcinoma (HCC) cell lines. PXD101was found to inhibit cell growth at a dose-dependent manner and induce histone acetylation in PLC/PRF/5, Hep3B and HepG2 cells. In PLC/PRF/5 and Hep3B cells which express hepatitis B-related genes (HBx, HBc and HBc), treatment with PXD101 resulted in apoptosis without a significant effect on viral gene expression. Exposure to PXD101 for up to 48 h had varying effects on the expression of 12 cellular genes with tumor suppressor functions, including p21, SOCS1, CMTM5, RASAL1, DLEC1, SFRP (-1, -2, -4 and -5), ADAMTS (-8 and -9). This study provided the basis for a phase II clinical trial of PXD101 in inoperable hepatitis-B associated HCC.
著者Ma BBY, Sung F, Tao Q, Poon FF, Lui VW, Yeo W, Chan SL, Chan ATC
期刊名稱Investigational New Drugs
出版年份2010
月份4
日期1
卷號28
期次2
出版社SPRINGER
頁次107 - 114
國際標準期刊號0167-6997
電子國際標準期刊號1573-0646
語言英式英語
關鍵詞Hepatitis B; Hepatocellular carcinoma; PXD101; Tumor suppressor genes
Web of Science 學科類別Oncology; ONCOLOGY; Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY

上次更新時間 2020-27-11 於 01:34